摘要
目的 评价美罗培南治疗重症血液系统疾病合并感染时的临床疗效及安全性。方法 采用回顾性多中心无选择性调查 (填表 )的方法 ,病例来自北京协和医院等 14家医院的血液科和肿瘤科 ,共观察急性白血病等 184 (包括 15名儿童 )例合并感染者使用美罗培南 ,剂量多为 0 .5～ 1.0 g,q8～ 12 h,疗程 <12 d(16 7/174 ) ,10例无法评价。结果 美罗培南治疗血液病合并感染的有效率 80 % (139/ 174 ,显效 +有效 ) ,细菌清除率为 5 1% (11/ 2 1) ,在合并败血症 16例中 ,13例有效 ;有一例异基因造血干细胞移植失败者合并 4次败血症 ,2次应用本药均显效 ,另一例接受非清髓性造血干细胞移植合并颅内感染也有效。本组美罗培南治疗的副作用为 2 .2 % (4/ 184 )。结论 美罗培南治疗血液病合并感染效果明显且较安全。
Object To evaluate the clinical effectiveness and safety of meropenem in the treatment of severe blood system diseases complicated with infections. Methods A retrospective multi-center random study protocol (questionnaire) was adopted and the subjects came from the hematological departments and oncological departments of 14 hospitals in China including Peking Union Hospital. Total 184 acute leukemia and other subjects (including 15 children) complicated with infection were observed. The dosage of meropenem (Mepem) was 0.5～1.0g, q8～12h for most of the subjects and the treatment course was less than 12 days (167/174). Among them, 10 subjects could not be evaluated. Results The effectiveness rate was 80% (139/174, significantly effective plus effective) and the clearance rate of bacterial was 51% (11/21) in the treatment of blood system diseases complicated with infection. The effectiveness rate was 13/16 for blood system diseases complicated with septicemia. One subject who failed allogenetic hemopoietic stem cell transplantation complicated with septicemia for four times, in which the drug was used two times and was well responsive. It was also effective in one patient who received non-marrow clearance hemopoietic stem cell transplantation complicated with intracranial infection. The occurrence rate of side effect of Mepem in this group was 2.2% (4/184). Conclusion Meropenem is significantly effective and safe in the treatment of blood diseases complicated with infections.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2004年第8期462-464,共3页
Chinese Journal of Antibiotics
